Organic compounds -- part of the class 532-570 series – Organic compounds – Hydroxamic acids – chalcogen analogs or salts thereof
Reexamination Certificate
2011-08-02
2011-08-02
Davis, Brian J (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Hydroxamic acids, chalcogen analogs or salts thereof
C514S575000
Reexamination Certificate
active
07989660
ABSTRACT:
Antibacterial compounds of formula I are provided:As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.
REFERENCES:
patent: 2772281 (1956-11-01), Holley et al.
patent: 5925659 (1999-07-01), Patchett et al.
patent: 6218389 (2001-04-01), Almstead et al.
patent: 6228988 (2001-05-01), Floyd et al.
patent: 6281245 (2001-08-01), Patel et al.
patent: 6358987 (2002-03-01), Beckett et al.
patent: 7358359 (2008-04-01), Andersen et al.
patent: 2001/0053555 (2001-12-01), Patel et al.
patent: 2004/0229955 (2004-11-01), Andersen et al.
patent: 2006/0154988 (2006-07-01), Andersen et al.
patent: 2007/0244197 (2007-10-01), Andersen et al.
patent: 2008/0269221 (2008-10-01), Andersen et al.
patent: 2009/0163496 (2009-06-01), Andersen et al.
patent: 2009/0247506 (2009-10-01), Andersen et al.
patent: 2010/0324025 (2010-12-01), Andersen et al.
patent: WO 96/26223 (1996-08-01), None
patent: WO-97/05105 (1997-02-01), None
patent: WO 97/42179 (1997-11-01), None
patent: WO 98/15525 (1998-04-01), None
patent: WO-98/15525 (1998-04-01), None
patent: WO 98/18754 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO-98/22494 (1998-05-01), None
patent: WO-99/06340 (1999-02-01), None
patent: WO 99/39704 (1999-08-01), None
patent: WO 99/57097 (1999-11-01), None
patent: WO-00/59874 (2000-10-01), None
patent: WO 00/61134 (2000-10-01), None
patent: WO-02/50081 (2002-06-01), None
patent: WO 02/50081 (2002-06-01), None
patent: WO 03/000448 (2003-01-01), None
patent: WO 03/004488 (2003-01-01), None
patent: WO-03/004488 (2003-01-01), None
patent: WO 2004/007444 (2004-01-01), None
patent: WO-2004/062601 (2004-07-01), None
Database CAPLUS on STN, Acc. No. 1999:113626, Almstead et al., WO 9906340 (Feb. 11, 1999) (abstract).
Pirrung et al., “A Convenient Procedure for the Preparation of Amino Acid Hydroxamates from Esters” J. Org. Chem. 60: 8084-8085, 1995.
Ngu et al., “A New and Efficient Solid Phase Synthesis of Hydroxamic Acids” J. Org. Chem. 62: 7088-7089, 1997.
Mellor et al., “N-Fmoc-Aminooxy-2-Chlorotrityl Polystyrene Resin: A Facile Solid-Phase Methodology for the Synthesis of Hydroxamic Acids” Tetrahedron Letters 38 (18): 3311-3314, 1997.
Khan et al., “A Facile and Convenient Solid-Phase Procedure for Synthesizing Nucleoside Hydroxamic Acids” Tetrahedron Letters 39: 8031-8034, 1998.
Jackman et al., “Antibacterial Agents that Target Lipid a Biosynthesis in Gram-Negative Bacteria” J. Biological Chemistry 275 (15): 11002-11009, 2000.
Pirrung et al., “Inhibition of the Antibacterial Target UDP-(3-O-acyl)-N-acetyglucosamine Deacetylase (LpxC) . . . ” J. Med. Chem. 45: 4359-4370, 2002.
Kline et al., “Potent, Novel in Vitro Inhibitors of thePseudomonas aeruginosaDeacetylase LpxC” J. Med. Chem. 45: 3112-3129, 2002.
Database CAPLUS on STN, Acc. No. 2002:429779; Kline et al., Journal of Medicinal Chemistry (2002),. 45(14), p. 3112-3129 (abstract).
Database CAPLUS on STN, Acc. No. 1997:224101, Kleinman, WO 9705105 (Feb. 13, 1997) abstract.
Database CAPLUS on STN, Acc. No. 1997:746038,.Patchett et al., WO 9742179 (Nov. 13, 1997) abstract.
Database CAPLUS on STN, Acc. No. 1999:113626, Almstead et al., WO 9906340 (Feb. 11, 1999) abstract.
Nicolaus, B. J. R., “Symbiotic Approach to Drug Design,” inDecision Making in Drug Research, F. Gross (ed.) (1993), pp. 173-186; published by Raven Press, New York.
Chen, M. H., et al. “Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis,” Bioorg. Med. Chem. Lett., vol. 9, No. 3, Feb. 8, 1999, pp. 313-318.
Jackman et al., “Antibacterial agents that target lipid A biosynthesis in gram-negative bacteria. Inhibition of diverse UDP-3-O-(r-3-hydroxymyristoyl)-n-acetylglucosamine deacetylases by substrate analogs containing, zinc binding motifs,” J Biol Chem. Apr. 14, 2000;275(15):11002-9.
Pirrung et al., “High-Throughput Catch-and-Release Synthesis of Oxazoline Hydroxamates. Structure-Activity Relationships in Novel Inhibitors ofEscherichia coliLpxC: In Vitro Enzyme Inhibition and Antibacterial Properties,” J. Am. Chem. Soc., vol. 125, No. 6, Feb. 12, 2003, pp. 1575-1586.
Nicolaus, B. J. R., “Symbiotic Approach to Drug Design,” Decision Making in Drug Research, 1983, pp. 173-186.
U.S. Appl. No. 11/981,279, filed Oct. 31, 2007, Andersen, et al.
Angus, et al.; “Outer Membrane Permeability inPseudomonas aeruginosa: Comparison of a Wild-type with an Antibiotic supersusceptible Mutant”; Antimocriob. Agents Chemother (1982); vol. 21(2), pp. 299-309.
Bergeron, et al.; “Effects of C-4 Stereochemistry and C-4′ Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues”; J. Med. Chem (1999); vol. 42, pp. 2432-2440.
Boyce, et al.; “Total Synthesis of Thiangazole, a Novel Naturally Occurring HIV-1 Inhibitor from Polyangium sp”; Tetrahedron (1995); Vo. 51(26), pp. 7321-7330.
Brooks & Summers; “Modulators of Leukotriene Biosynthesis and Receptor Activation”; J. Med. Chem. (1996) vol. 39(14), pp. 2629-2654.
Charette & Chua; “Mild Method for the Synthesis of Thiazolines from Secondary and Tertiary Amides”; J. Org. Chem. (1998); vol. 63, pp. 908-909.
Fernandez, et al.; “Novel Synthesis of 2-Thiazolines”; Tetrahedron Lett. (2000); vol. 41, pp. 3381-3384.
Galeotti, et al.; “Synthesis of Peptidyl Aldehydes from Thiazolidines”; Tetrahedron Lett. (1997); vol. 38(14), pp. 2459-2462.
Gilbert, S. Banker, et al., editor; Modern Pharmaceutics 3rd edition (1996); pp. 596; Marcel Dekker, Inc., NY.
Hyland, et al.; “Cloning, Expression and Purification of UDP-3-O-Acyl-GlcNAc Deacetylase from Pseudomonas Aeruginosa: A metalloamidase of the Lipid A Biosynthesis Pathway”; J. Bacteriol. (1997); vol. 179(6), pp. 2029-2037.
International Preliminary Report on Patentability; PCT International Application No. PCT/US2004/000433; Applicant: Chiron Corp.; Issued: Jul. 8, 2005, (4 pgs.).
International Search Report; PCT International Patent Application No. PCT/US2004/000433; Applicant: Chiron Corp.; Issued: Jan. 19, 2005, (2 pgs.).
Ito, et al.; “Synthetic Reactions by Complex Catalysts XXXV, A Facile Synthetic Method of Cyclic Imino Ethers and Imino Thioethers”; Syn. Commun. (1974); vol. 4(2), pp. 97-103.
Ito, et al.; “Synthetic Reactions by Complex Catalysts, XXXI. A Novel and Versatile Method of Heterocycle Synthesis”; J. Am. Chem. Soc. (1973); vol. 95(13), pp. 4447-4448.
Jeng & Delombaert; “Endothelin Converting Enzyme Inhibitors”; Curr. Pharma. Design (1997); vol. 3, pp. 597-614.
Jones, R.N.; “Resistance Patterns Among Nosocomial Pathogens”; Chest (2001); vol. 119(2)(Supplement), pp. 397S-404S.
Manfred E. Wolff, editor; Burger's Medicinal Chemistry and Drug Discovery 5th edition (1995);vol. 1, pp. 975-977; John Wiley & Sons, NY.
Matsuda, et al.; “Nucleosides and Nucleotides. 95. Improved Synthesis of 1-(2-Azido-2-deoxy-.beta.-D-arabinofuranosyl)cytosine (Cytarazid and -thymine, Inhibitory Spectrum of Cytarazid on the Growth of Various Human Tumor Cells in Vitro”; J. Med. Chem (1991); vol. 34, pp. 999-1002.
Nikaido, H.; “Antibiotic Resistance Caused by Gram-negative multidrug Efflux Pumps”; Clin. Infect. Dis. (1998); vol. 27 (Supplement 1), pp. S32-S41.
Pattenden & Thom; “Naturally Occurring Linear Fused Thiazoline-thiazole Containing Metabolites:Total Synthesis of (-)-Didehydromirabazole A, a Cytotoxic Alkaloid from Blue-Green Algae”; J. Chem. Soc. Perkin Trans. (1993); pp. 1629-1636.
Raman, et al.; “Titanium Iv-mediated Tandem Deprotection-Cyclodehydration of Protected Cysteine N-Amides: Biomimetic Syntheses of Thiazoline-and T
Andersen Niels H.
Bowman Jason
Erwin Alice
Harwood Eric
Kline Toni
Davis Brian J
Foley & Lardner LLP
Novartis Vaccines and Diagnostics Inc.
University of Washington
LandOfFree
Antibacterial agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibacterial agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2774980